14 Sep 2020 Oblique Therapeutics is honored to participate as speaker to the 2nd Edition RAS- Targeted Drug Development Congress 15th September 2020
29 Jun 2020 Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms
11 Jun 2020 Oblique Therapeutics AB has identified a potentially important epitope for generation of SARS-CoV-2 antibodies
10 Oct 2019 Oblique Therapeutics is on EU-Startups top 10 list -“10 European biotech startups to look out for in 2019 and beyond”
17 Jul 2019 We are proud to have been recognised by StartUp City Magazine as one of the most promising European Biotech startups in 2019!
